Cullen Capital Management LLC Has $124.81 Million Holdings in Becton, Dickinson and Company $BDX

Cullen Capital Management LLC boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 824,720 shares of the medical instruments supplier’s stock after purchasing an additional 95,559 shares during the period. Cullen Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $124,805,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BDX. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $25,000. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at about $26,000. Meeder Asset Management Inc. lifted its position in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares in the last quarter. Main Street Group LTD bought a new stake in Becton, Dickinson and Company during the 1st quarter worth about $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $29,000. Institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 11,704 shares of company stock worth $1,963,618. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on BDX shares. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. TD Cowen raised their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Barclays increased their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Stock Down 0.7%

Shares of NYSE:BDX opened at $190.58 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock has a market cap of $52.51 billion, a price-to-earnings ratio of 57.40, a P/E/G ratio of 13.53 and a beta of 0.19. The company has a 50 day moving average of $162.48 and a 200-day moving average of $160.73. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.